Poland· PL-100173878
Byetta
A exenatide product containing exenatidum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Exenatide is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BJ01 (exenatide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Exenatide · ATC A10BJ01
10 / 19 countries
- Belgiumprice
- Finlandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of exenatide costs, country by country.
Normalised to the WHO defined daily dose (15 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Exenatide · price per daily dose (15 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$0.26
The record
At a glance
URPL (Poland)- Active substance
- Exenatidum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- A10BJ01
- ATC class
- Exenatide
- Defined daily dose
- 15 mcg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990020669
- gtin05909990020676
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
404 interactions on record for exenatide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Exenatide · interactions on record
404 records
- 3 severe
- 359 moderate
- 42 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- MannitolA06AD16moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Exenatide in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumByetta 10 µgAstraZeneca
- SpainBYETTA 10 MICROGRAMOS SOLUCION INYECTABLE EN PLUMA PRECARGADAAstrazeneca Ab
- IrelandBYETTA 10 micrograms Solution for injectionAstraZeneca AB
- United KingdomBydureon 2mg powder and solvent for prolonged-release suspension for injection pre-filled pensAstraZeneca UK Ltd
- United StatesByettaAstraZeneca Pharmaceuticals LP
- FinlandBydureonAstraZeneca AB
- ItalyBYDUREON*4 penne preriempite Bcise SC 2 mg 0,85 ml rilascio prolungatoASTRAZENECA AB
- NorwayBydureonAstraZeneca
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7b366f27-423b-41bc-829a-c290eb239298 GET /v1/drugs/7b366f27-423b-41bc-829a-c290eb239298?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "10 mcg",
"packaging": "05909990020669 ¦ Rp ¦ EU/1/06/362/003 ¦ 34605\n1 wstrzykiwacz 2,4 ml\n05909990020676 ¦ Rp ¦ EU/1/06/362/004 ¦ 34606\n3 wstrzykiwacze 2,4 ml",
"substance": "Exenatidum 10 mcg/1 dawka",
"common_name": "Exenatidum",
"pl_product_id": "100173878",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about exenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.